Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jan;84(2):290–295. doi: 10.1054/bjoc.2000.1587

Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model

S E Holwell 1, B T Hill 2, M C Bibby 1
PMCID: PMC2363703  PMID: 11161390

Abstract

Anti-vascular effects of the novel Vinca alkaloid, vinflunine have been investigated in the MAC 15A transplantable murine colon adenocarcinoma model and compared with those induced by the most recently identified clinically useful third generation Vinca. Administration of the maximum tolerated dose of either vinflunine (50 mg kg−1) or vinorelbine (8 mg kg−1) resulted in significant tumour growth delay with subsequent histological analysis revealing substantial haemorrhagic necrosis. This suggested possible anti-vascular effects and these were confirmed by Hoechst 33342 perfusion studies. Vinflunine, currently undergoing Phase I trials in Europe, was found to be at least as effective as the clinically active vincristine and vinorelbine in this model and, remarkably, produced anti-vascular effects at doses much lower than the maximum tolerated dose. Although vinflunine caused apoptosis in HUVEC monolayer cultures this event did not occur within the first 8 hours of exposure whereas vascular shutdown in vivo was observed within the first 4 hours. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: anti-vascular effects, vinflunine, vinorelbine, MAC 15A murine tumour

Full Text

The Full Text of this article is available as a PDF (639.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALGIRE G. H., LEGALLAIS F. Y., ANDERSON B. F. Vascular reactions of normal and malignant tissues in Vivo. VI. The role of hypotension in the action of components of podophyllin on transplanted sarcomas. J Natl Cancer Inst. 1954 Feb;14(4):879–893. [PubMed] [Google Scholar]
  2. Baguley B. C., Holdaway K. M., Thomsen L. L., Zhuang L., Zwi L. J. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer. 1991;27(4):482–487. doi: 10.1016/0277-5379(91)90391-p. [DOI] [PubMed] [Google Scholar]
  3. Berthaud P., Le Chevalier T., Ruffie P., Baldeyrou P., Arriagada R., Besson F., Tursz T. Phase I-II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer. 1992;28A(11):1863–1865. doi: 10.1016/0959-8049(92)90023-u. [DOI] [PubMed] [Google Scholar]
  4. Budman D. R. New vinca alkaloids and related compounds. Semin Oncol. 1992 Dec;19(6):639–645. [PubMed] [Google Scholar]
  5. Budman D. R. Vinorelbine (Navelbine): a third-generation vinca alkaloid. Cancer Invest. 1997;15(5):475–490. doi: 10.3109/07357909709047587. [DOI] [PubMed] [Google Scholar]
  6. Chaplin D. J., Dougherty G. J. Tumour vasculature as a target for cancer therapy. Br J Cancer. 1999 Jul;80 (Suppl 1):57–64. [PubMed] [Google Scholar]
  7. Cowen S. E., Bibby M. C., Double J. A. Characterisation of the vasculature within a murine adenocarcinoma growing in different sites to evaluate the potential of vascular therapies. Acta Oncol. 1995;34(3):357–360. doi: 10.3109/02841869509093989. [DOI] [PubMed] [Google Scholar]
  8. Dark G. G., Hill S. A., Prise V. E., Tozer G. M., Pettit G. R., Chaplin D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997 May 15;57(10):1829–1834. [PubMed] [Google Scholar]
  9. Fumoleau P., Delgado F. M., Delozier T., Monnier A., Gil Delgado M. A., Kerbrat P., Garcia-Giralt E., Keiling R., Namer M., Closon M. T. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 1993 Jul;11(7):1245–1252. doi: 10.1200/JCO.1993.11.7.1245. [DOI] [PubMed] [Google Scholar]
  10. Fumoleau P., Delozier T., Extra J. M., Canobbio L., Delgado F. M., Hurteloup P. Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience. Semin Oncol. 1995 Apr;22(2 Suppl 5):22–29. [PubMed] [Google Scholar]
  11. Grosios K., Holwell S. E., McGown A. T., Pettit G. R., Bibby M. C. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer. 1999 Dec;81(8):1318–1327. doi: 10.1038/sj.bjc.6692174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hayes A. J., Li L. Y., Lippman M. E. Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment. BMJ. 1999 Mar 27;318(7187):853–856. doi: 10.1136/bmj.318.7187.853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hill B. T., Fiebig H. H., Waud W. R., Poupon M. F., Colpaert F., Kruczynski A. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer. 1999 Mar;35(3):512–520. doi: 10.1016/s0959-8049(98)00416-x. [DOI] [PubMed] [Google Scholar]
  14. Hill S. A., Lonergan S. J., Denekamp J., Chaplin D. J. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer. 1993;29A(9):1320–1324. doi: 10.1016/0959-8049(93)90082-q. [DOI] [PubMed] [Google Scholar]
  15. Johnson S. A., Harper P., Hortobagyi G. N., Pouillart P. Vinorelbine: an overview. Cancer Treat Rev. 1996 Mar;22(2):127–142. doi: 10.1016/s0305-7372(96)90032-8. [DOI] [PubMed] [Google Scholar]
  16. Kruczynski A., Barret J. M., Etiévant C., Colpaert F., Fahy J., Hill B. T. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol. 1998 Mar 1;55(5):635–648. doi: 10.1016/s0006-2952(97)00505-4. [DOI] [PubMed] [Google Scholar]
  17. Kruczynski A., Colpaert F., Tarayre J. P., Mouillard P., Fahy J., Hill B. T. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol. 1998;41(6):437–447. doi: 10.1007/s002800050764. [DOI] [PubMed] [Google Scholar]
  18. Laws A. L., Matthew A. M., Double J. A., Bibby M. C. Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer. 1995 Jun;71(6):1204–1209. doi: 10.1038/bjc.1995.234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Le Chevalier T., Brisgand D., Douillard J. Y., Pujol J. L., Alberola V., Monnier A., Riviere A., Lianes P., Chomy P., Cigolari S. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994 Feb;12(2):360–367. doi: 10.1200/JCO.1994.12.2.360. [DOI] [PubMed] [Google Scholar]
  20. Phillips R. M., Bibby M. C., Double J. A. Experimental correlations of in vitro drug sensitivity with in vivo responses to ThioTEPA in a panel of murine colon tumours. Cancer Chemother Pharmacol. 1988;21(2):168–172. doi: 10.1007/BF00257366. [DOI] [PubMed] [Google Scholar]
  21. Quinn P. K., Bibby M. C., Cox J. A., Crawford S. M. The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumours. Br J Cancer. 1992 Aug;66(2):323–330. doi: 10.1038/bjc.1992.264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Romero A., Rabinovich M. G., Vallejo C. T., Perez J. E., Rodriguez R., Cuevas M. A., Machiavelli M., Lacava J. A., Langhi M., Romero Acuña L. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol. 1994 Feb;12(2):336–341. doi: 10.1200/JCO.1994.12.2.336. [DOI] [PubMed] [Google Scholar]
  23. Tozer G. M., Prise V. E., Wilson J., Locke R. J., Vojnovic B., Stratford M. R., Dennis M. F., Chaplin D. J. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 1999 Apr 1;59(7):1626–1634. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES